Anupam Rasayan
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Anupam Rasayan is strategically transforming into a diversified specialty chemicals platform, focusing on high-growth sectors such as pharmaceuticals and electronics. Management's optimistic outlook is supported by the successful integration of recent acquisitions, including Jayhawk Fine Chemicals and Bliss GVS Pharma, which are expected to enhance operational capabilities and expand market reach. The robust pipeline of over 90 molecules and a strong order book of ₹14,646 Crores provide significant revenue visibility, aligning with Vista's forecast of a 20-30% CAGR in the stand-alone business over the next 3-5 years. However, execution risks related to integration and elevated debt levels remain watchpoints. The specialty chemicals industry is experiencing stable growth, bolstered by strong domestic demand and favorable trade agreements, although competitive pricing pressures and rising input costs could impact margins. Overall, Vista's expected upside of 41.85% reflects confidence in Anupam's ability to capitalize on structural growth opportunities while navigating potential challenges in the near term
Why We Like This Stock
- Successful integration of acquisitions is expected to enhance operational capabilities and market reach
- A strong pipeline of over 90 molecules and a substantial order book provide significant revenue visibility
- Focus on high-growth sectors like pharmaceuticals and electronics aligns with industry trends and demand
Things To Watch Out For
- Execution risks related to the integration of recent acquisitions could impact operational performance
- Elevated debt levels may pose financial scrutiny and limit flexibility in capital allocation
- Competitive pricing pressures and rising input costs could challenge margin stability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,475 | 1,437 | 2,365 | 2,719 | 3,380 |
| Profit Before Tax (Cr.) | 236 | 198 | 254 | 318 | 396 |
| PBT Margin | 16.0% | 13.8% | 10.7% | 11.7% | 11.7% |
| Net Profit (Cr.) | 189 | 154 | 202 | 252 | 233 |
| Earnings Per Share | 13.2 | 7.7 | 13.2 | 16.4 | 20.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Deven Choksey | ► Accumulate | 1,374 | 19-Aug-2026 |
| ICICI Securities | ► Add | 1,345 | 19-Aug-2026 |
Company Overview
Show Company Profile
Anupam Rasayan India Ltd engages in the custom synthesis and manufacturing of specialty chemicals in India, Europe, Japan, Singapore, China, North America, and internationally. It operates through two segments: Life Science related Specialty Chemicals and Other Specialty Chemicals. The company offers life science related specialty chemicals, such as agro intermediates and agro active ingredients for the agrochemicals industry; anti-bacterial and ultraviolet protection intermediates and ingredients for the personal care industry; and intermediates and key starting materials for active pharmaceutical ingredients. It provides other specialty chemicals used in various end-user segments, including specialty pigments, specialty dyes, and polymer additives. The company was incorporated in 1984 and is headquartered in Surat, India.